Christine E. Edmonds

Christine E. Edmonds

Auto-generated profile, based on publicly available information

Christine E. Edmonds

Department of Radiology, Hospital of the University of Pennsylvania , Philadelphia, PA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2022 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
OFOluwadamilola M. Fayanju
Oluwadamilola M. Fayanju
CEChristine E. Edmonds
Christine E. Edmonds
SRSylvia A. Reyes
Sylvia A. Reyes
CACletus Arciero
Cletus Arciero
VBVivian J. Bea
Vivian J. Bea
KJKathie-Ann Joseph
Kathie-Ann Joseph

4 November 2022 in Seminars in Ultrasound, CT and MRI
Verified
Journal Article
Closed access
CEChristine E. Edmonds
Christine E. Edmonds
SOSophia R. O'BRien
Sophia R. O'BRien
ECEmily F. Conant
Emily F. Conant

21 June 2022 in Cancer Imaging
Verified
Journal Article
Open access
PDF file
CEChristine E. Edmonds
Christine E. Edmonds
SOSophia R. O’bRien
Sophia R. O’bRien
DMDavid A. Mankoff
David A. Mankoff
APAustin R. Pantel
Austin R. Pantel
The goals of precision oncology are to provide targeted drug therapy based on each individual’s specific tumor biology, and to enable the prediction and early assessment of treatment response to allow treatment modification when necessary. Thus, precision oncology aims to maximize treatment success while minimizing the side effects of inadequate or suboptimal therapies. Molecular imaging, through noninvasive assessment of clinically relevant tumor biomarkers across the entire disease burden, has the potential to revolutionize clinical oncology, including breast oncology. In this article, we review breast cancer positron emission tomography (PET) imaging biomarkers for providing early response assessment and predicting treatment outcomes. For 2-18fluoro-2-deoxy-D-glucose (FDG), a marker of cellular glucose metabolism that is well established for staging multiple types of malignancies including breast cancer, we highlight novel applications for early response assessment. We then review current and future applications of novel PET biomarkers for imaging the steroid receptors, including the estrogen and progesterone receptors, the HER2 receptor, cellular proliferation, and amino acid metabolism.

13 September 2023 in Academic Radiology
Verified
Journal Article
Closed access
SGSara P. Ginzberg
Sara P. Ginzberg
CEChristine E. Edmonds
Christine E. Edmonds
FDFarouk Dako
Farouk Dako
TDTerrilynn Donnell
Terrilynn Donnell
AWArmenta L. Washington
Armenta L. Washington
LNLinda W. Nunes
Linda W. Nunes

3 May 2022 in Clinical and Translational Imaging
Verified
Journal Article
Closed access
PDF file
SOSophia R. O’bRien
Sophia R. O’bRien
CEChristine E. Edmonds
Christine E. Edmonds
DKDanielle Katz
Danielle Katz
DMDavid A. Mankoff
David A. Mankoff
APAustin R. Pantel
Austin R. Pantel

1 October 2024 in JCO Oncology Practice
Verified
Journal Article
Closed access
RMRitika Manik
Ritika Manik
CGConnor B. Grady
Connor B. Grady
SGSara P. Ginzberg
Sara P. Ginzberg
CEChristine E. Edmonds
Christine E. Edmonds
ECEmily F Conant
Emily F Conant
OFOluwadamilola M. Fayanju
Oluwadamilola M. Fayanju
PURPOSE: Black and White women undergo screening mammography at similar rates, but racial disparities in breast cancer outcomes persist. To assess potential contributors, we investigated delays in follow-up after abnormal imaging by race/ethnicity. METHODS: Women who underwent screening mammography at our urban academic center from January 2015 to February 2018 and received a Breast Imaging Reporting and Data System 0 assessment were included. Kaplan-Meier estimates described distributions of time between diagnostic events from (1) screening to diagnostic imaging and (2) diagnostic imaging to biopsy. Multivariable logistic regression models estimated the associations between race/ethnicity and receipt of follow-up within 15 and 30 days. RESULTS: Two thousand five hundred and fifty-four women were included (48.6% non-Hispanic [NH] Black, 38.2% NH White, 13.1% other/unknown). Median time between screening and diagnostic imaging varied by race/ethnicity (White: 7 days [IQR, 2-14]; Black: 12 days [IQR, 7-23]; other/unknown: 9 days [IQR, 5-21]). There were similar disparities in days between diagnostic imaging and biopsy (White: 12 [IQR, 7-24]; Black: 21 [IQR, 13-37]; other/unknown: 16 [IQR, 9-30]) and between screening and biopsy (White: 20 [IQR, 11-41]; Black: 35 [IQR, 22-63]; other/unknown: 27.5 [IQR, 17-42]). After adjustment, odds of diagnostic imaging follow-up within 15 days of screening were lower for Black versus White women (odds ratio, 0.59 [95% CI, 0.44 to 0.80]; P < .001). CONCLUSION: In this diverse cohort, disparities in timely diagnostic follow-up after abnormal breast screening were observed, with Black women waiting 1.75 times as long as White women to obtain a tissue diagnosis. National guidelines for time to diagnostic follow-up may facilitate more timely breast cancer care and potentially affect outcomes.